SAN DIEGO, November 21, 2019 – Imbria Pharmaceuticals, Inc. today announced that Imbria Pharmaceuticals will participate in the Evercore ISI HealthCONx Conference on Tuesday, December 3, 2019 at the Four Seasons Hotel – Back Bay, Boston, MA. David-Alexandre C. Gros, M.D., President and Chief Executive Officer, and Heidi Henson, Chief Financial Officer, will participate in a “fireside chat” beginning at 1:35 pm ET.
About Imbria Pharmaceuticals
Imbria Pharmaceuticals uses our deep understanding of cellular energy metabolism to develop novel therapies designed to substantially improve the lives of patients with life-altering diseases. Our clinical stage pipeline is focused on restoring or improving the cell’s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. Our lead program, IMB-101, is currently in Phase 1 clinical development, and will be further developed for two separate indications: refractory angina and heart failure. Additional product candidates, IMB-202 and IMB-203, are designed to address cellular energy deficiency in patients with rare genetic mutations in mitochondrial metabolism, including those with propionic acidemia and other inborn errors of metabolism. For additional information, please visit www.imbria.com.